Market Closed -
Swiss Exchange
09:01:30 26/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.946
CHF
|
-6.34%
|
|
+0.42%
|
+31.39%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
177.1
|
169.5
|
157.3
|
127
|
91.05
|
4.903
|
Enterprise Value (EV)
1 |
119.9
|
135.7
|
146.6
|
126.8
|
101
|
-0.9356
|
P/E ratio
|
-6.07
x
|
-7.8
x
|
-5.32
x
|
-2.86
x
|
-2.02
x
|
-0.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.8
x
|
14.6
x
|
20.9
x
|
12.9
x
|
5.86
x
|
1.18
x
|
EV / Revenue
|
13.4
x
|
11.7
x
|
19.4
x
|
12.8
x
|
6.5
x
|
-0.23
x
|
EV / EBITDA
|
-5.13
x
|
-10.1
x
|
-9.6
x
|
-4.92
x
|
-6.09
x
|
-0.16
x
|
EV / FCF
|
-7.08
x
|
-9.55
x
|
-8.91
x
|
-4.95
x
|
-9.26
x
|
-0.06
x
|
FCF Yield
|
-14.1%
|
-10.5%
|
-11.2%
|
-20.2%
|
-10.8%
|
-1,773%
|
Price to Book
|
0.91
x
|
0.98
x
|
1.12
x
|
1.01
x
|
0.86
x
|
0.94
x
|
Nbr of stocks (in thousands)
|
3,079
|
3,095
|
3,114
|
3,791
|
4,441
|
6,810
|
Reference price
2 |
57.50
|
54.75
|
50.50
|
33.50
|
20.50
|
0.7200
|
Announcement Date
|
28/02/19
|
18/03/20
|
25/02/21
|
10/03/22
|
08/03/23
|
22/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
8.933
|
11.6
|
7.541
|
9.878
|
15.54
|
4.157
|
EBITDA
1 |
-23.35
|
-13.43
|
-15.27
|
-25.78
|
-16.57
|
5.711
|
EBIT
1 |
-30.74
|
-20.13
|
-22
|
-31.9
|
-21.77
|
0.5062
|
Operating Margin
|
-344.08%
|
-173.57%
|
-291.81%
|
-322.96%
|
-140.12%
|
12.18%
|
Earnings before Tax (EBT)
1 |
-31.32
|
-21.61
|
-29.89
|
-41.41
|
-43.37
|
-101.2
|
Net income
1 |
-29.21
|
-21.64
|
-29.87
|
-41.27
|
-43.37
|
-101.2
|
Net margin
|
-327.04%
|
-186.61%
|
-396.12%
|
-417.78%
|
-279.07%
|
-2,434.99%
|
EPS
2 |
-9.478
|
-7.022
|
-9.491
|
-11.72
|
-10.13
|
-14.04
|
Free Cash Flow
1 |
-16.93
|
-14.21
|
-16.46
|
-25.6
|
-10.9
|
16.59
|
FCF margin
|
-189.55%
|
-122.52%
|
-218.27%
|
-259.18%
|
-70.14%
|
399.04%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
290.42%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/19
|
18/03/20
|
25/02/21
|
10/03/22
|
08/03/23
|
22/03/24
|
Fiscal Period: December |
2023 S1
|
---|
Net sales
1 |
4.5
|
EBITDA
1 |
-6.3
|
EBIT
1 |
-9.8
|
Operating Margin
|
-217.78%
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
23/08/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
9.91
|
-
|
Net Cash position
1 |
57.2
|
33.8
|
10.6
|
0.16
|
-
|
5.84
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.5984
x
|
-
|
Free Cash Flow
1 |
-16.9
|
-14.2
|
-16.5
|
-25.6
|
-10.9
|
16.6
|
ROE (net income / shareholders' equity)
|
-14.1%
|
-11.8%
|
-18.8%
|
-29.8%
|
-36.4%
|
-181%
|
ROA (Net income/ Total Assets)
|
-8.48%
|
-6.21%
|
-7.66%
|
-12.3%
|
-9.48%
|
0.45%
|
Assets
1 |
344.3
|
348.4
|
389.8
|
334.3
|
457.6
|
-22,532
|
Book Value Per Share
2 |
63.00
|
55.60
|
45.00
|
33.10
|
23.80
|
0.7700
|
Cash Flow per Share
2 |
19.60
|
12.90
|
6.100
|
2.760
|
1.150
|
0.8100
|
Capex
1 |
0.89
|
0.19
|
1.23
|
0.34
|
0.49
|
-
|
Capex / Sales
|
9.95%
|
1.67%
|
16.28%
|
3.39%
|
3.17%
|
-
|
Announcement Date
|
28/02/19
|
18/03/20
|
25/02/21
|
10/03/22
|
08/03/23
|
22/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +31.39% | 7.46M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|